Investing.com -- Morgan Stanley upgraded its rating on Zealand Pharma (NASDAQ: ZEAL) shares to Overweight from Equal Weight, ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.

Initiated in December 2024, the Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment. Zealand Pharma remains on track to initiate ...

Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...

With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...

Roche's move for the asset comes shortly after Zealand started the phase 2b ZUPREME-1 trial of petrelintide in people overweight or obese, and ahead of the ZUPREME-2 study in overweight or obese ...

In addition, William Blair has initiated coverage on Zealand Pharma with a Market Perform rating, acknowledging the potential of its lead drug candidate, petrelintide, in the obesity market.

Investing.com -- Zealand Pharma shares surged more than 41% on Wednesday after announcing a $5.3 billion licensing deal with Roche for its GLP-1 obesity therapy petrelintide.